<DOC>
	<DOCNO>NCT03075956</DOCNO>
	<brief_summary>Estetrol ( E4 ) develop two indication support woman health care : first E4 combine progestin , [ drospirenone ( DRSP ) ] use new combined oral contraceptive ( COC ) prevention pregnancy secondly , E4 use alone new hormone replacement therapy ( HRT ) treatment menopause relate symptom . The current clinical trial design collect detailed information PK profile , safety tolerability different dosage E4 , give orally solid tablet .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Estetrol ( E4 ) After Single Multiple Oral Doses Healthy Female Volunteers</brief_title>
	<detailed_description>This open-label , single-center , randomize , two-period , single multiple oral dose study 27 healthy female volunteer . After screen period , eligible subject ( n=27 ) receive single oral dose 5 , 15 , 45 mg E4 ( Period 1 ) . After least 14-day washout , 18 subject continue study ( Period 2 ) . They receive 15 mg E4 daily 14 consecutive day .</detailed_description>
	<criteria>Postmenopausal premenopausal overtly healthy female subject , determine medical history , physical examination include breast examination , gynecological examination [ include cervical smear ( Pap smear ) ] , vital sign , ECG , laboratory test perform . Between age 18 55 year inclusive time signing informed consent . Between BMI 18 35 kg/m2 inclusive body weight ≥ 45kg . Negative serum pregnancy test result screen negative urine pregnancy test result Day 1 Period 1 . Venous access sufficient allow blood sample per protocol . Reliable willing available duration study willing comply study procedure . Have give write informed consent ( IC ) approve relevant EC govern site . Negative test result select drug abuse cotinine screen visit ( include alcohol ) checkin Period 1 ( include alcohol ) . Use : 1 . Any prescription drug and/or herbal supplement act CYP3A4 function , within 28 day prior first study dose administration study completion . 2 . Any overthecounter medication dietary supplement ( vitamin include ) within 14 day prior first study dose study completion . Currently breastfeed . Subjects euthyroid condition . Known hypersensitivity investigational product ingredient . History malignancy . History presence prolong QT interval . Abnormal arterial tension . History presence disease major system organ class ( e.g . cardiovascular , pulmonary , renal , hepatic , gastrointestinal , reproductive , endocrinological , neurological , psychiatric orthopedic disease ) judge Investigator . History presence migraine aura age migraine without aura &gt; 35 year old . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study . History presence immunodeficiency diseases include positive HIV test result , positive hepatitis B antigen hepatitis C test result . Smokers . History illicit drug alcohol abuse within 12 month prior first dose evidence abuse . Donation loss ≥ 450 mL blood within 1 month prior initial study drug administration . ≥ 250 mL blood within 2 week prior initial study drug administration . Previous completion withdrawal study . Participation another investigational drug clinical study within 1 month ( 30 day ) receive investigational drug within last 3 month ( 90 day ) prior study entry . Subjects participate oral contraceptive clinical study , use Food Drug Administration ( FDA ) / European Union ( EU ) approve active ingredient , may enrol 2 month ( 60 day ) complete precede study . Sponsor , Contract Research Organization ( CRO ) Investigator 's site personnel directly affiliate study . Is judged Investigator unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>